Alderley Park, 23 February 2022 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces the expansion of the Company’s therapeutic pipeline with two additional programmes, BVX002 and BVX003, both entering the early stages of drug development.
BVX002 and BVX003 target novel cancer-specific twin antigen fingerprints, incorporating the Company’s proprietary Bi-Cygni® technology, alongside the established and validated Antibody Drug Conjugate (ADC) mechanism-of-action, to form the next-generation of Bi-Cygni® ADCs with superior cancer selectivity.These programmes enable the targeting of several haematological and solid tumour cancer indications and will be developed alongside BiVictriX’s lead asset, BVX001, which has a lead indication in Acute Myeloid Leukaemia(AML). This pipeline expansion demonstrates the broad utility of the Bi-Cygni®approach across a wide range of solid tumour and haematological cancer types which constitute areas of significant unmet medical need, and further highlights the potential expansion of the platform in novel areas of immuno-oncology.
The pipeline expansion follows the Company’s recent filing of four new patent applications to further strengthen its growing intellectual property portfolio in the UK and internationally. The patents, which will form part of a new patent family for BiVictriX, relate to several novel cancer-specific antigen pairs or “fingerprints” across a range of oncology indications, which have been identified by the Company.
Tiffany Thorn, Chief Executive of BiVictriX, commented: “This is an exciting announcement for the Company. The expansion of our current therapeutic pipeline to include two additional programmes moving into the early stages of development is a significant milestone and enables BiVictriX to demonstrate the broad utility of its promising new approach to cancer therapeutic development across a wide range of difficult-to-treat cancers, including both solid tumour and haematological indications that currently represent areas of urgent unmet medical need. We are focused on working to fast-track the development of these two new programmes alongside our lead asset, BVX001, to reach early preclinical proof of concept in the short to medium term.”